HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy.


Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
08 2019
Historique:
received: 06 12 2018
revised: 25 01 2019
accepted: 28 01 2019
pubmed: 3 3 2019
medline: 20 5 2020
entrez: 3 3 2019
Statut: ppublish

Résumé

During breast cancer progression, tumor cells acquire multiple malignant features. The transcription factors and cell cycle regulators high mobility group A2 (HMGA2) and BTB and CNC homology 1 (Bach-1) are overexpressed in several cancers, but the mechanistic understanding of how HMGA2 and Bach-1 promote cancer development has been limited. We found that HMGA2 and Bach-1 are overexpressed in breast cancer tissues and their expression correlates positively in tumors but not in normal tissues. Individual HMGA2 or Bach-1 knockdown downregulates expression of both proteins, suggesting a mutual stabilizing effect between the two proteins. Importantly, combined HMGA2 and Bach-1 knockdown additively decrease cell proliferation, migration, epithelial-to-mesenchymal transition, and colony formation, while promoting apoptotic cell death via upregulation of caspase-3 and caspase-9. First the first time, we show that HMGA2 and Bach-1 overexpression in tumors correlate positively and that the proteins cooperatively suppress a broad range of malignant cellular properties, such as proliferation, migration, clonogenicity, and evasion of apoptotic cell death. Thus, our observations suggest that combined targeting of HMGA2 and Bach1 may be an effective therapeutic strategy to treat breast cancer.

Identifiants

pubmed: 30825204
doi: 10.1002/jcp.28397
doi:

Substances chimiques

BACH1 protein, human 0
Basic-Leucine Zipper Transcription Factors 0
HMGA2 Protein 0
HMGA2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17714-17726

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Behzad Mansoori (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Ali Mohammadi (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Zahra Asadzadeh (Z)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Solmaz Shirjang (S)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mahsa Minouei (M)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Fereydoon Abedi Gaballu (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Neda Shajari (N)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Tohid Kazemi (T)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Morten F Gjerstorff (MF)

Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Pascal H G Duijf (PHG)

University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH